<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4277">
  <stage>Registered</stage>
  <submitdate>28/01/2014</submitdate>
  <approvaldate>28/01/2014</approvaldate>
  <nctid>NCT02049515</nctid>
  <trial_identification>
    <studytitle>A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07</studytitle>
    <scientifictitle>A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>IPI-145-12</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Lymphocytic Leukemia</healthcondition>
    <healthcondition>Small Lymphocytic Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - IPI-145 (duvelisib)
Treatment: drugs - Ofatumumab

Experimental: IPI-145 - IPI-145 is administered orally and supplied as 5 mg and 25 mg formulated capsules.

Active Comparator: Ofatumumab - Ofatumumab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg/5mL and 1000 mg/50 mL


Treatment: drugs: IPI-145 (duvelisib)
PI3K Inhibitor

Treatment: drugs: Ofatumumab


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall response rate (ORR)</outcome>
      <timepoint>Until disease progression or unacceptable toxicity assessed for up to 2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment-emergent adverse events (TEAEs) and changes in safety laboratory values</outcome>
      <timepoint>Enrollment through 30 days after the last dose of either IPI-145 or Ofatumumab</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response</outcome>
      <timepoint>Every 12-20 weeks; for an average duration of response follow-up of 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival (PFS)</outcome>
      <timepoint>From date of enrollment until the date of first documentation of progression or date of death from any cause, whatever came first, assessed up to 2 years.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Received either IPI-145 or ofatumumab while participating in study IPI-145-07 and
             experienced radiologically-confirmed disease progression

          -  Diagnosis of active CLL or SLL that meets at least 1 of the International Workshop on
             Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria for requiring treatment

          -  Measurable disease with a lymph node or tumor mass &gt;1.5 cm in at least one dimension
             as assessed by computed tomography (CT)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Must meet the following laboratory parameters:

               1. Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) =3 x
                  upper limit of normal (ULN)

               2. Total bilirubin =1.5 x ULN

               3. Serum creatinine =2.0 x ULN

               4. Hemoglobin =8.0 g/dL with or without transfusion support

               5. Platelet count =10,000 µL with or without transfusion support

          -  For women of childbearing potential (WCBP): negative serum ß-human chorionic
             gonadotropin (ßhCG) pregnancy test within 1 week before first dose (WCBP defined as a
             sexually mature woman who has not undergone surgical sterilization or who has not been
             naturally post-menopausal for at least 24 consecutive months [women =55 years] or 12
             consecutive months [women &gt;55 years])

          -  Willingness of male and female subjects who are not surgically sterile or
             postmenopausal to use medically acceptable methods of birth control from the first
             dose of study drug to 30 days after the last dose of duvelisib and for 12 months after
             last dose of ofatumumab. Sexually active men, and women using oral contraceptive
             pills, should also use barrier contraception

          -  Ability to voluntarily sign consent for and adhere to the entire study visit schedule
             and all protocol requirements

          -  Signed and dated institutional review board (IRB)/independent ethics committee
             (IEC)-approved informed consent form (ICF) before any study specific screening
             procedures are performed</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Discontinued study participation in Verastem-sponsored IPI-145-07 study

          -  Greater than 3 months from confirmed progressive disease on Study IPI-145-07

          -  History of Richter's transformation or prolymphocytic leukemia

          -  Autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenia purpura (ITP) that
             is uncontrolled or requires &gt;20 mg daily (QD) of prednisone (or equivalent) to
             maintain hemoglobin &gt;8.0 g/dL or platelets &gt;10,000 µL without transfusion support

          -  Known central nervous system (CNS) lymphoma or leukemia; subjects with symptoms of CNS
             disease must have a negative computed tomography (CT) scan or negative diagnostic
             lumbar puncture prior to first dose

          -  Use of any anticancer medication from documented PD on Study IPI-145-07 to enrollment
             (Note: corticosteroids to manage CLL/SLL-related symptoms are allowed)

          -  Ongoing systemic bacterial, fungal, or viral infections at the time of initiation of
             study treatment (defined as requiring IV antimicrobial, antifungal or antiviral
             agents) ( Subjects on antimicrobial, antifungal or antiviral prophylaxis are not
             specifically excluded if all other inclusion/exclusion criteria are met and there is
             no evidence of active infection at Screening and/or Cycle 1 Day 1 (predose))

          -  Human immunodeficiency virus (HIV) infection

          -  Prior, current, or chronic hepatitis B or hepatitis C infection

          -  History of alcohol abuse or chronic liver disease (other than metastatic disease to
             the liver)

          -  Unable to receive prophylactic treatment for pneumocystis and herpes simplex virus
             (HSV)

          -  Baseline QT interval corrected with Fridericia's method (QTcF) &gt;480 ms NOTE: this
             criterion does not apply to subjects with a right or left bundle branch block (BBB)

          -  Concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ
             of the cervix, bladder, or prostate not requiring treatment. Subjects with previous
             malignancies are eligible provided that they have been disease-free for =2 years

          -  History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia
             requiring medication or mechanical control within the last 6 months

          -  Unstable or severe uncontrolled medical condition (eg, unstable cardiac function,
             unstable pulmonary condition), or any important medical illness or abnormal laboratory
             finding that would, in the Investigator's judgment, increase the subject's risk while
             participating in this study

          -  Prior surgery or gastrointestinal dysfunction that may affect drug absorption (eg,
             gastric bypass surgery, gastrectomy)

          -  Subjects to receive duvelisib: Administration of medications or foods that are strong
             inhibitors or inducers of cytochrome P450 (CYP) 3A within 2 weeks of starting
             duvelisib

          -  Major surgery or invasive intervention within 4 weeks prior to first dose

          -  Pregnant or breastfeeding women

          -  Subjects to receive ofatumumab: hypersensitivity to ofatumumab or its excipients.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Bedford Park</hospital>
    <hospital> - East Melbourne</hospital>
    <hospital> - Melbourne</hospital>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <postcode>3058 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Linz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Niklaas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Argenteuil Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bobigny</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Caen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clermont Ferrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>La Roche Sur Yon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Limoges Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Köln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rostock</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Gyor</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kaposvár</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Pecs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szeged</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Catania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lecce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Meldola</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ravenna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rimini</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Palmerston North</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Pamplona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bournemouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oxford</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sutton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Verastem, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A Phase 3 (extension) clinical trial to examine the efficacy of IPI-145 monotherapy or
      ofatumumab monotherapy in subjects with Chronic Lymphocytic Leukemia (CLL) or Small
      Lymphocytic Lymphoma (SLL) who experienced disease progression after treatment with IPI-145
      or Ofatumumab in Study IPI-145-07.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02049515</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Hagop Youssoufian, MD</name>
      <address>Verastem, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>